



**Rule Category:**  
Pharmaceutical

**Ref: No:**  
2017-PH-003

**Version Control:**  
Version No.1.0

**Effective Date:**  
20 January 2018

**Last Update:**  
10-01-2023



# Liraglutide for obesity management

## Adjudication Guideline

### Abstract

#### For Members

Liraglutide for Obesity management is an injectable prescription medicine which is indicated for weight loss as an adjunct to reduced calorie diet and increased physical activity

#### For Medical Professionals

Liraglutide for Obesity management is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of:

- 30 kg/m<sup>2</sup> or greater (obese) (1) or
- 27 kg/m<sup>2</sup> or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia)

**Approved by:**  
Daman

**Responsible:**  
Medical Standards & Research

**Related Adjudication Guidelines:** None

#### Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by the National Health Insurance Company – Daman PJSC (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.

Doc Ctrl No.:	TEMP/349	Version No.:	1	Revision No.:	0	Date of Issue:	13.10.2016	Page No(s).:	1 of 6
---------------	----------	--------------	---	---------------	---	----------------	------------	--------------	--------

## Scope

This Adjudication Rule highlights the coverage and payment requirements of Liraglutide for Obesity management by Daman as per policy terms and conditions. It also highlights the dosage for 4 months (16 weeks) according to FDA.

## Adjudication Policy

### Eligibility / Coverage Criteria

Liraglutide for obesity management is a speciality drug, which can be prescribed by the following clinicians:

Eligible clinician specialities
Internal Medicine
Endocrinology
Family Medicine

### Medical professionals:

- Before the provider submits preauthorisation request, they should fill in the questionnaires (kindly refer to appendix B) and submit with the request.
- Upon successful eligibility, the first authorization prescription will be 4months (16weeks), however the drug will be dispensed on 2 monthly basis (i.e. first initial prescription and one refill prescription).
- After the completion of the 16 weeks, an updated questionnaire should be submitted with each prescription showing the continued favourable response to the medication (evident as maintenance or further weight loss of the patient).
- All preauthorisation requests subsequent to the first one, will follow standard authorization protocol as relevant to the individual member's Schedule of Benefits.
- Claim will be rejected if the request has not been authorized.

### General eligibility requirements for pharmacies to dispense the medication:

- Ability to track patient's history.
- Ability to store the prescription.
- Ability to record and document patient weight (kg) upon each monthly dispense encounter.

*\*N.B: Daman may request the patient's data from the pharmacy prior to any approval and for audit purposes.*

**Dosage:**

Recommended dosage of Liraglutide for Obesity management is 3mg daily.

**Dose Escalation Schedule**

Week	Daily Dose
1	0.6 mg
2	1.2 mg
3	1.8 mg
4	2.4 mg
5 and onward	3 mg

*Evaluate the change in body weight 16 weeks after initiating Liraglutide for Obesity management and discontinue Liraglutide for Obesity management if the patient has not lost more than 4% of baseline body weight, since it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment.*

**Important facts:**

- Liraglutide for Obesity management is not indicated for the treatment of type 2 diabetes mellitus.
- Liraglutide (6mg/ml) and Liraglutide (6mg/ml) both are same active ingredient, therefore is not covered when used together.
- Liraglutide for Obesity management should not be used in combination with any other GLP-1 receptor agonist.
- Liraglutide for Obesity management should not be used in patients taking insulin.
- Safety and efficacy has not been established in people with cardiovascular disease, with history of pancreatitis or concurrent use with other products intended for weight loss including prescription drugs, over the counter drugs, herbal preparations.
- Liraglutide for Obesity management is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with MEN 2.
- Liraglutide for Obesity management is contraindicated in patients with prior hypersensitivity reactions to Liraglutide.
- Liraglutide for Obesity management is contraindicated during pregnancy.
- Liraglutide for Obesity management should be discontinued in nursing mothers.

**Use of Liraglutide for Obesity management in paediatric age group:**

Safety and efficacy has not been established in paediatric age group patients. Liraglutide for Obesity management is not recommended for use in paediatric population.

**Requirements for Coverage**

- ICD and CPT codes must be coded to the highest level of specificity.
- Failure to submit, upon request or when requesting a clinical history, indication the need for testing will result in rejection of claim.

## Non-Coverage

Plan	Coverage
Visitor plan	Not covered
Basic plan	Not covered
Enhanced plan	Coverage as per SOBs
Thiqa	Covered

## Payment and Coding Rules

Please apply regulator payment rules and regulations and relevant coding manuals for ICD, CPT.

## Denial codes

Code	Code description
MNEC-003	Service is not clinically indicated based on good clinical practice
MNEC-004	Service is not clinically indicated based on good clinical practice, without additional supporting diagnoses/activities
MNEC-005	Service /supply may be appropriate , but too frequent
NCOV-003	Service(s) is (are) not covered
PRC-002	Payment is included in allowance for another service

## Adjudication Examples

### Example 1

**Question:** A 30 year old female started Liraglutide for Obesity management with baseline weight of 90kg and height of 5 foot and 6 inches and BMI of 32.0. After 16 weeks patient is evaluated for weight loss and her new weight is 84 kg and her new BMI is 29.9. Can this patient continue Liraglutide for Obesity management for another 16 weeks?

**Answer:** Yes, she can continue, as she lost more than 4% of her baseline body weight.

### Example 2

**Question:** A 30 year old male started Liraglutide for Obesity management with baseline weight of 90kg and height of 5 foot and 6 inches and BMI of 32.0. After 16 weeks patient is evaluated for weight loss and his new weight is 88 kg and her new BMI is 31.3 Can this patient continue Liraglutide for Obesity management for another 16 weeks?

**Answer:** No, the patient did not meet the criteria to continue Liraglutide for Obesity management for another 16 weeks as per FDA. Claim will be rejected.

## Appendices

### A. References

- [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2014/206321Orig1s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf)

2. <https://www.karger.com/Article/FullText/442721>
3. <http://www.obesitynetwork.ca/files/FULLREPORTfinalENG.pdf>
4. [https://ec.europa.eu/health/documents/community-register/2015/20150323131125/anx\\_131125\\_en.pdf](https://ec.europa.eu/health/documents/community-register/2015/20150323131125/anx_131125_en.pdf)
5. [https://www.nice.org.uk/guidance/es14/resources/obese-overweight-with-risk-factors-liraglutide-Liraglutide for Obesity management-pdf-1158115342021](https://www.nice.org.uk/guidance/es14/resources/obese-overweight-with-risk-factors-liraglutide-Liraglutide%20for%20Obesity%20management-pdf-1158115342021)

**B. Questionnaire :**

<https://www.damanhealth.ae/main/pdf/support/Questionnaire/LiraglutideforobesitymanagementQuestionnaire.pdf>

**Liraglutide for obesity management Questionnaire**

Patient card number:  
 Patient age:  
 Patient contact no:  
 Provider name:  
 Prescribing physician specialty:

**CLINICAL CRITERIA**

Diagnosis (check the applicable):

- Over-weight
- Obesity
- BMI 27.0 – 27.9
- BMI 28.0 – 28.9
- BMI 29.0 – 29.9
- BMI 30.0 – 30.9
- BMI 31.0 – 31.9
- BMI 32.0 – 32.9
- BMI 33.0 – 33.9
- BMI 34.0 – 34.9
- BMI 35.0 – 35.9
- BMI 36.0 – 36.9
- BMI 37.0 – 37.9
- BMI 38.0 – 38.9
- BMI 39.0 – 39.9
- BMI 40.0 – 44.9
- BMI 45.0 – 49.9
- BMI 50.0 – 59.9
- BMI 60.0 – 69.9
- BMI 70.0 or greater

**Co-morbidities :**

- Heart disease
- Diabetes mellitus type 2
- Dyslipidaemia
- Hypertension
- Endocrine disorders
- Eating disorders

Other co-morbidities (please specify): \_\_\_\_\_

**First prescription :**

Date of first prescription : \_\_\_\_/\_\_\_\_/\_\_\_\_  
DD MM YYYY

Height (cm)	Weight (kg)	BMI

Liraglutide (Saxenda)	Dose	No. of pens dispensed
First week (1 <sup>st</sup> month)		
Second week (1 <sup>st</sup> month)		
Third week (1 <sup>st</sup> month)		
Fourth week (1 <sup>st</sup> month)		
Second month		
Third month		
Fourth month		

Patient received diet plan:

 YES  NO

Patient receive an exercise plan:

 YES  NO**Repeat prescription :**

Liraglutide (Saxenda®) dispense month	Dose	No of pens dispensed	Weight ( kg)	BMI
Month no-				
Month no -				
Month no -				
Month no -				
Month no -				
Month no -				
Month no -				
Month no -				
Month no -				
Month no -				
Month no -				
Month no -				
Month no -				
Month no -				

**C. Revision History**

Date	Change(s)
20 January 2018	Release of V1.0
10-01-2023	Questionnaire link update